Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 14.3% during trading on Friday . The company traded as high as C$0.40 and last traded at C$0.40. 813,546 shares were traded during trading, an increase of 19% from the average session volume of 681,348 shares. The stock had previously closed at C$0.35.
Hemostemix Stock Up 11.4 %
The firm has a 50-day moving average price of C$0.12 and a two-hundred day moving average price of C$0.09. The company has a market capitalization of C$33.98 million, a P/E ratio of -19.50 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- What is diluted earnings per share (Diluted EPS)?
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Compound Interest and Why It Matters When Investing
- 3 Buy-and-Hold Stocks for Long-Term Growth
- What is a Dividend King?
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
